EthOss Regeneration

EthOss Regeneration is a UK dental regenerative medicine and medical device company focused on synthetic bone graft materials for dentistry and oral surgery. Its lead and apparently core commercial product is EthOss Bone Graft, a fully synthetic, animal-free graft composed of beta tricalcium phosphate and calcium sulphate that is used to support host bone regeneration in implant and augmentation procedures. The company markets its approach as "True Host Bone Regeneration" and emphasizes in-situ hardening, membrane-free handling in many cases, and full resorption over time. EthOss was founded in 2013 by Dr. Peter Fairbairn and Dr. Paul Harrison, launched commercially after CE marking in 2015, and has built an international footprint in more than 75 countries. In January 2026, Lifco announced the acquisition of a majority stake in Ethoss Regeneration, with the business to be consolidated within Lifco's Dental business area.